Clinical trials
Bone Cancer Metastatic clinical trials
Below are recruiting bone cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT07162480RecruitingPhase 2
New drug for aggressive adenoid cystic carcinoma
This trial tests a new drug called Puxitatug Samrotecan (AZD8205) for people with an aggressive form of adenoid cystic carcinoma. It aims to see if the drug can shrink tumors or slow the disease in patients whose cancer has advanced or spread.
Houston, TexasAges 18 years+ - NCT07146074Recruiting
Early radiation vs. observation for high-risk bone metastases
This trial tests whether giving radiation therapy early to high-risk but pain-free or nearly pain-free bone metastases can prevent future problems, compared to waiting and monitoring them. It is for people whose cancer has spread to multiple bones and who have certain risky features in those spots.
Wilrijk, AntwerpAges 18 years+ - NCT06775743RecruitingPhase 2
Combination therapy and radiation for EGFR-mutant lung cancer after resistance
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT05821556RecruitingPhase 2
New drug combo test for untreated metastatic pancreatic cancer
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
Naples, ItalyAges 18 years+ - NCT07213557RecruitingPhase 2
Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Naples, ItaliaAges 18 years+ - NCT06576037RecruitingPhase 1
Study of CBP-1019 with chemo for advanced solid tumors
This trial tests a new drug called CBP-1019 combined with chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have a type of cancer that hasn't gotten better with other therapies.
Houston, TexasAges 18 years+ - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT07633756RecruitingPhase 1
Testing RB1-negative Leiomyosarcoma Treatment with REC-617
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
Houston, TexasAges 18 years+ - NCT06249191RecruitingPhase 1/Phase 2
Mosunetuzumab plus chemo for untreated high-grade B-cell lymphoma
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Portland, OregonAges 18–75 - NCT05333458RecruitingPhase 2
Atezolizumab plus selinexor for advanced alveolar soft tissue sarcoma
This Phase 2 trial tests whether combining atezolizumab with selinexor can slow or shrink advanced alveolar soft part sarcoma (ASPS) in people age 12 and older. It may help by improving the immune system’s ability to fight the cancer and stopping cancer cell growth signals.
Los Angeles, CaliforniaAges 12 years+ - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Birmingham, AlabamaAges 2–21 - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Duarte, CaliforniaAges 18 years+ - NCT05687123RecruitingPhase 1
Adding sunitinib to Lutathera for pancreatic neuroendocrine tumors
This early-phase study tests whether adding sunitinib (a targeted pill) to Lutathera (a radioactive treatment) works better for people with advanced pancreatic neuroendocrine tumors. It also checks safety, since this combination has not been widely studied yet.
Duarte, CaliforniaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+
Hear when a new Bone Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone cancer metastatic?
- Yes. Clin2 currently lists 741 recruiting bone cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.